58 related articles for article (PubMed ID: 35247953)
1. Delayed gametocyte clearance in
Salazar YEAR; Louzada J; Puça MCSdB; Guimarães LFF; Vieira JLF; Siqueira AMd; Gil JP; Brito CFAd; Sousa TNd
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0120423. PubMed ID: 38411047
[TBL] [Abstract][Full Text] [Related]
2. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
Ingram RJ; Crenna-Darusallam C; Soebianto S; Noviyanti R; Baird JK
Malar J; 2014 Dec; 13():488. PubMed ID: 25495607
[TBL] [Abstract][Full Text] [Related]
3. Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study.
Puaprasert K; Chu C; Saralamba N; Day NPJ; Nosten F; White NJ; Dondorp AM; Imwong M
Malar J; 2018 Nov; 17(1):427. PubMed ID: 30442143
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
Puça MCSB; Rodrigues DF; Salazar YEAR; Louzada J; Fontes CJF; Daher A; Pereira DB; Fernandes Vieira JL; Carvalho LH; de Brito CFA; Gil JP; de Sousa TN
J Antimicrob Chemother; 2024 Jun; ():. PubMed ID: 38870082
[TBL] [Abstract][Full Text] [Related]
5. Primaquine dose and the risk of haemolysis and Plasmodium vivax recurrence: pooling the available data to reassure the unconvinced.
Millat-Martínez P; Bassat Q
Lancet Infect Dis; 2024 Feb; 24(2):116-118. PubMed ID: 37748498
[No Abstract] [Full Text] [Related]
6. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Quinn JC; McCarthy S
N Engl J Med; 2019 May; 380(19):1875. PubMed ID: 31067383
[No Abstract] [Full Text] [Related]
7. Relapsing
Martins EB; de Pina-Costa A; Mamani RF; Lupi O; Calvet GA; Bressan CS; Silva MFB; Siqueira AM; da Silva S; Zanini GM; de Fátima Ferreira-da-Cruz M; Daniel-Ribeiro CT; Brasil P
Malariaworld J; 2024; 15():8. PubMed ID: 38737169
[No Abstract] [Full Text] [Related]
8. Host metabolomic responses in recurrent P. vivax malaria.
Yakubu MN; Mwangi VI; Netto RLA; Alecrim MGC; Alves JRS; Almeida ACG; Santos GF; Lima GS; Machado LS; Koolen HHF; Guimarães TP; Chaves AR; Vaz BG; Monteiro WM; Costa FTM; Lacerda MVG; Gardinassi LG; de Melo GC
Sci Rep; 2024 Mar; 14(1):7249. PubMed ID: 38538661
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the antimalarial activity of SAM13-2HCl with morpholine amide (SKM13 derivative) against antimalarial drug-resistant Plasmodium falciparum and Plasmodium berghei infected ICR mice.
Hong H; Moon K; Trinh TT; Eom TH; Park H; Kim HS; Yeo SJ
Parasites Hosts Dis; 2024 Feb; 62(1):42-52. PubMed ID: 38443769
[TBL] [Abstract][Full Text] [Related]
10. Identification of breeding habitats and kdr mutations in Anopheles spp. in South Korea.
Hong H; Eom TH; Trinh TT; Tuan BD; Park H; Yeo SJ
Malar J; 2023 Dec; 22(1):381. PubMed ID: 38104158
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
Chamchoy K; Sudsumrit S; Thita T; Krudsood S; Patrapuvich R; Boonyuen U
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010986. PubMed ID: 36508454
[TBL] [Abstract][Full Text] [Related]
12. Cost-Benefit Analysis of Tafenoquine for Radical Cure of
Suh J; Kim JH; Kim JD; Kim C; Choi JY; Lee J; Yeom JS
J Korean Med Sci; 2022 Jul; 37(27):e212. PubMed ID: 35818703
[TBL] [Abstract][Full Text] [Related]
13. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
[TBL] [Abstract][Full Text] [Related]
14. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
[TBL] [Abstract][Full Text] [Related]
15. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
16. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
18. Primaquine treatment and relapse in Plasmodium vivax malaria.
Rishikesh K; Saravu K
Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
